Q3 2023 Results
Company overview
Financial review
Conclusions
Innovation: Pipeline overview
Financial performance
Cardiovascular
Immunology
Appendix
Innovation: Clinical trials
Neuroscience
Oncology
pelacarsen - Antisense oligonucleotide (ASO)
targeting Lp(a)
NCT04023552 Lp(a)HORIZON (CTQJ230A12301)
Indication
Phase
Patients
Primary
Outcome
Measures
Arms
Intervention
Secondary prevention of cardiovascular events in patients with elevated levels
of lipoprotein(a)
Phase 3
8323
Time to the first occurrence of MACE (cardiovascular death, non-fatal MI,
non-fatal stroke and urgent coronary re-vascularization)
TQJ230 80 mg injected monthly subcutaneously or matched placebo
Patients with a history of Myocardial infarction or Ischemic Stroke, or a clinically
significant symptomatic Peripheral Artery Disease, and Lp(a) ≥ 70 mg/dL
Target
Patients
Readout
2025
Milestone(s)
Publication
TBD
50 Investor Relations | Q3 2023 Results
References
Abbreviations
Other
NOVARTIS | Reimagining MedicineView entire presentation